These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1115 related articles for article (PubMed ID: 21680574)
41. Cytometric and biochemical characterization of human breast cancer cells reveals heterogeneous myoepithelial phenotypes. Leccia F; Nardone A; Corvigno S; Vecchio LD; De Placido S; Salvatore F; Veneziani BM Cytometry A; 2012 Nov; 81(11):960-72. PubMed ID: 22791584 [TBL] [Abstract][Full Text] [Related]
42. Spectral overlap-free quantum dot-based determination of benzo[a]pyrene-induced cancer stem cells by concurrent monitoring of CD44, CD24 and aldehyde dehydrogenase 1. Shim Y; Song JM Chem Commun (Camb); 2015 Feb; 51(11):2118-21. PubMed ID: 25536409 [TBL] [Abstract][Full Text] [Related]
43. Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047. Cirenajwis H; Smiljanic S; Honeth G; Hegardt C; Marton LJ; Oredsson SM Anticancer Drugs; 2010 Nov; 21(10):897-906. PubMed ID: 20838207 [TBL] [Abstract][Full Text] [Related]
44. CD44(high)CD24(low) molecular signature determines the Cancer Stem Cell and EMT phenotype in Oral Squamous Cell Carcinoma. Ghuwalewala S; Ghatak D; Das P; Dey S; Sarkar S; Alam N; Panda CK; Roychoudhury S Stem Cell Res; 2016 Mar; 16(2):405-17. PubMed ID: 26926234 [TBL] [Abstract][Full Text] [Related]
45. Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24- phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression. Zhang Y; Yao F; Yao X; Yi C; Tan C; Wei L; Sun S Oncol Rep; 2009 Apr; 21(4):1113-21. PubMed ID: 19288016 [TBL] [Abstract][Full Text] [Related]
46. Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes. Park SY; Kwon HJ; Choi Y; Lee HE; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH Mod Pathol; 2012 Feb; 25(2):185-96. PubMed ID: 22037257 [TBL] [Abstract][Full Text] [Related]
47. The prognostic role of cancer stem cells in breast cancer: a meta-analysis of published literatures. Zhou L; Jiang Y; Yan T; Di G; Shen Z; Shao Z; Lu J Breast Cancer Res Treat; 2010 Aug; 122(3):795-801. PubMed ID: 20571867 [TBL] [Abstract][Full Text] [Related]
48. Clinicopathological analysis of breast ductal carcinoma in situ with ALDH1-positive cancer stem cells. Tsukabe M; Shimazu K; Morimoto K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Kim SJ; Noguchi S Oncology; 2013; 85(4):248-56. PubMed ID: 24192633 [TBL] [Abstract][Full Text] [Related]
49. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Balic M; Lin H; Young L; Hawes D; Giuliano A; McNamara G; Datar RH; Cote RJ Clin Cancer Res; 2006 Oct; 12(19):5615-21. PubMed ID: 17020963 [TBL] [Abstract][Full Text] [Related]
50. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer. West NR; Murray JI; Watson PH Oncogene; 2014 Mar; 33(12):1485-94. PubMed ID: 23584474 [TBL] [Abstract][Full Text] [Related]
51. Implications of Different Cancer Stem Cell Phenotypes in Breast Cancer. DA Cruz Paula A; Lopes C Anticancer Res; 2017 May; 37(5):2173-2183. PubMed ID: 28476780 [TBL] [Abstract][Full Text] [Related]
52. Characterization of sphere‑forming cells with stem‑like properties from the gastric cancer cell lines MKN45 and SGC7901. Wang X; Zou F; Deng H; Fu Z; Li Y; Wu L; Wang Z; Liu L Mol Med Rep; 2014 Dec; 10(6):2937-41. PubMed ID: 25270642 [TBL] [Abstract][Full Text] [Related]
53. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). Ma F; Li H; Wang H; Shi X; Fan Y; Ding X; Lin C; Zhan Q; Qian H; Xu B Cancer Lett; 2014 Oct; 353(2):153-9. PubMed ID: 25130168 [TBL] [Abstract][Full Text] [Related]
54. Aldehyde dehydrogenase 1 expression is associated with poor prognosis in patients with esophageal squamous cell carcinoma. Minato T; Yamamoto Y; Seike J; Yoshida T; Yamai H; Takechi H; Yuasa Y; Furukita Y; Goto M; Bando Y; Tangoku A Ann Surg Oncol; 2013 Jan; 20(1):209-17. PubMed ID: 22847125 [TBL] [Abstract][Full Text] [Related]
55. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Abraham BK; Fritz P; McClellan M; Hauptvogel P; Athelogou M; Brauch H Clin Cancer Res; 2005 Feb; 11(3):1154-9. PubMed ID: 15709183 [TBL] [Abstract][Full Text] [Related]
56. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast. Oon ML; Thike AA; Tan SY; Tan PH Breast Cancer Res Treat; 2015 Feb; 150(1):31-41. PubMed ID: 25677743 [TBL] [Abstract][Full Text] [Related]
57. Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast. DA Cruz Paula A; Marques O; Rosa AM; DE Fátima Faria M; Rêma A; Lopes C Anticancer Res; 2014 Mar; 34(3):1427-34. PubMed ID: 24596390 [TBL] [Abstract][Full Text] [Related]
58. Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer. Seo AN; Lee HJ; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY Br J Cancer; 2016 May; 114(10):1109-16. PubMed ID: 27115469 [TBL] [Abstract][Full Text] [Related]
59. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers. De Brot M; Rocha RM; Soares FA; Gobbi H Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210 [TBL] [Abstract][Full Text] [Related]